Genital herpes is a common sexually transmitted disease. With the increase in population of various regions, there is also an increase in the rate of health issues around the world. As the rate of diseases grow, the treatment markets are also expected to grow substantially. With respect to sexually transmitted disease like genital herpes, its treatment market includes different drug types like Acyclovir, Valacyclovir and Famciclovir. The indication of genital herpes include HSV-1 and HSV-2.
The rising prevalence of shingles or herpes zoster in the older population is one of the key drivers responsible for the market’s growth. According to the center for disease control and prevention (CDC), almost one in every three individuals in the US are likely to develop shingles during their lifetime. People aged 50 years and above can develop this disease due to weakened immune system. Complications associated with this disease such as post-herpetic neuralgia (PHN) can cause severe pain in the areas where the rashes occurred due to shingles. People administered with immunosuppressants in the past can also develop the disease. CDC recommends that one dose of the zoster vaccine must be prescribed to adults who are 60 years and above to reduce the probability of the disease and PHN. This will drive the demand for drugs for virus types such as herpes simplex and herpes zoster, subsequently fueling market growth.
This report provides a complete quantitative data and qualitative analysis on the global market for Herpes Treatment. Market size is analysed by country, product type, application, and competitors. Expanded coverage includes additional end-user industry breakdowns and in-depth producer profiles.
Prior to COVID-19, the global market for Herpes Treatment was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of xx% during 2021–2026, whereas post-COVID-19 scenario, the market for Herpes Treatment is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 2021–2026.
This report covers market size and forecasts of Herpes Treatment, including the following market information:
Global Herpes Treatment Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K MT)
Global Herpes Treatment Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K MT)
Global Herpes Treatment Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million) & (K MT)
Global Herpes Treatment Market Size by Company, 2019- 2020 (quarterly data), (US$ Million) & (K MT)
Key market players
Major competitors identified in this market include Gilead, GlaxoSmithKline, Merck, Novartis, Abbott, Mylan, Teva Pharmaceutical Industries, Vical, etc.
Based on the Region:
Asia-Pacific (China, Japan, South Korea, India and ASEAN)
North America (US and Canada)
Europe (Germany, France, UK and Italy)
Rest of World (Latin America, Middle East & Africa)
Based on the Type:
Acyclovir
Valacyclovir
Famciclovir
Based on the Application:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Drug Stores
The rising prevalence of shingles or herpes zoster in the older population is one of the key drivers responsible for the market’s growth. According to the center for disease control and prevention (CDC), almost one in every three individuals in the US are likely to develop shingles during their lifetime. People aged 50 years and above can develop this disease due to weakened immune system. Complications associated with this disease such as post-herpetic neuralgia (PHN) can cause severe pain in the areas where the rashes occurred due to shingles. People administered with immunosuppressants in the past can also develop the disease. CDC recommends that one dose of the zoster vaccine must be prescribed to adults who are 60 years and above to reduce the probability of the disease and PHN. This will drive the demand for drugs for virus types such as herpes simplex and herpes zoster, subsequently fueling market growth.
This report provides a complete quantitative data and qualitative analysis on the global market for Herpes Treatment. Market size is analysed by country, product type, application, and competitors. Expanded coverage includes additional end-user industry breakdowns and in-depth producer profiles.
Prior to COVID-19, the global market for Herpes Treatment was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of xx% during 2021–2026, whereas post-COVID-19 scenario, the market for Herpes Treatment is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 2021–2026.
This report covers market size and forecasts of Herpes Treatment, including the following market information:
Global Herpes Treatment Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K MT)
Global Herpes Treatment Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K MT)
Global Herpes Treatment Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million) & (K MT)
Global Herpes Treatment Market Size by Company, 2019- 2020 (quarterly data), (US$ Million) & (K MT)
Key market players
Major competitors identified in this market include Gilead, GlaxoSmithKline, Merck, Novartis, Abbott, Mylan, Teva Pharmaceutical Industries, Vical, etc.
Based on the Region:
Asia-Pacific (China, Japan, South Korea, India and ASEAN)
North America (US and Canada)
Europe (Germany, France, UK and Italy)
Rest of World (Latin America, Middle East & Africa)
Based on the Type:
Acyclovir
Valacyclovir
Famciclovir
Based on the Application:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Drug Stores
1.1 Research Scope
1.2 Market Segmentation
1.3 Research Objectives
1.4 Research Methodology
1.4.1 Research Process
1.4.2 Data Triangulation
1.4.3 Research Approach
1.4.4 Base Year
1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.5.2 Covid-19 Impact: Commodity Prices Indices
1.5.3 Covid-19 Impact: Global Major Government Policy
1.6 The Covid-19 Impact on Herpes Treatment Industry
1.7 COVID-19 Impact: Herpes Treatment Market Trends
2 Global Herpes Treatment Quarterly Market Size Analysis
2.1 Herpes Treatment Business Impact Assessment - COVID-19
2.1.1 Global Herpes Treatment Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
2.1.2 Global Herpes Treatment Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
2.2 Global Herpes Treatment Quarterly Market Size 2020-2021
2.3 COVID-19-Driven Market Dynamics and Factor Analysis
2.3.1 Drivers
2.3.2 Restraints
2.3.3 Opportunities
2.3.4 Challenges
3 Quarterly Competitive Assessment, 2020
3.1 Global Herpes Treatment Quarterly Market Size by Manufacturers, 2019 VS 2020
3.2 Global Herpes Treatment Factory Price by Manufacturers
3.3 Location of Key Manufacturers Herpes Treatment Manufacturing Factories and Area Served
3.4 Date of Key Manufacturers Enter into Herpes Treatment Market
3.5 Key Manufacturers Herpes Treatment Product Offered
3.6 Mergers & Acquisitions, Expansion Plans
4 Impact of Covid-19 on Herpes Treatment Segments, By Type
4.1 Introduction
1.4.1 Acyclovir
1.4.2 Valacyclovir
1.4.3 Famciclovir
4.2 By Type, Global Herpes Treatment Market Size, 2019-2021
4.2.1 By Type, Global Herpes Treatment Market Size by Type, 2020-2021
4.2.2 By Type, Global Herpes Treatment Price, 2020-2021
5 Impact of Covid-19 on Herpes Treatment Segments, By Application
5.1 Overview
5.5.1 Hospital Pharmacies
5.5.2 Retail Pharmacies
5.5.3 Online Pharmacies
5.5.4 Drug Stores
5.2 By Application, Global Herpes Treatment Market Size, 2019-2021
5.2.1 By Application, Global Herpes Treatment Market Size by Application, 2019-2021
5.2.2 By Application, Global Herpes Treatment Price, 2020-2021
6 Geographic Analysis
6.1 Introduction
6.2 North America
6.2.1 Macroeconomic Indicators of US
6.2.2 US
6.2.3 Canada
6.3 Europe
6.3.1 Macroeconomic Indicators of Europe
6.3.2 Germany
6.3.3 France
6.3.4 UK
6.3.5 Italy
6.4 Asia-Pacific
6.4.1 Macroeconomic Indicators of Asia-Pacific
6.4.2 China
6.4.3 Japan
6.4.4 South Korea
6.4.5 India
6.4.6 ASEAN
6.5 Rest of World
6.5.1 Latin America
6.5.2 Middle East and Africa
7 Company Profiles
7.1 Gilead
7.1.1 Gilead Business Overview
7.1.2 Gilead Herpes Treatment Quarterly Production and Revenue, 2020
7.1.3 Gilead Herpes Treatment Product Introduction
7.1.4 Gilead Response to COVID-19 and Related Developments
7.2 GlaxoSmithKline
7.2.1 GlaxoSmithKline Business Overview
7.2.2 GlaxoSmithKline Herpes Treatment Quarterly Production and Revenue, 2020
7.2.3 GlaxoSmithKline Herpes Treatment Product Introduction
7.2.4 GlaxoSmithKline Response to COVID-19 and Related Developments
7.3 Merck
7.3.1 Merck Business Overview
7.3.2 Merck Herpes Treatment Quarterly Production and Revenue, 2020
7.3.3 Merck Herpes Treatment Product Introduction
7.3.4 Merck Response to COVID-19 and Related Developments
7.4 Novartis
7.4.1 Novartis Business Overview
7.4.2 Novartis Herpes Treatment Quarterly Production and Revenue, 2020
7.4.3 Novartis Herpes Treatment Product Introduction
7.4.4 Novartis Response to COVID-19 and Related Developments
7.5 Abbott
7.5.1 Abbott Business Overview
7.5.2 Abbott Herpes Treatment Quarterly Production and Revenue, 2020
7.5.3 Abbott Herpes Treatment Product Introduction
7.5.4 Abbott Response to COVID-19 and Related Developments
7.6 Mylan
7.6.1 Mylan Business Overview
7.6.2 Mylan Herpes Treatment Quarterly Production and Revenue, 2020
7.6.3 Mylan Herpes Treatment Product Introduction
7.6.4 Mylan Response to COVID-19 and Related Developments
7.7 Teva Pharmaceutical Industries
7.7.1 Teva Pharmaceutical Industries Business Overview
7.7.2 Teva Pharmaceutical Industries Herpes Treatment Quarterly Production and Revenue, 2020
7.7.3 Teva Pharmaceutical Industries Herpes Treatment Product Introduction
7.7.4 Teva Pharmaceutical Industries Response to COVID-19 and Related Developments
7.8 Vical
7.8.1 Vical Business Overview
7.8.2 Vical Herpes Treatment Quarterly Production and Revenue, 2020
7.8.3 Vical Herpes Treatment Product Introduction
7.8.4 Vical Response to COVID-19 and Related Developments
8 Supply Chain and Sales Channels Analysis
8.1 Herpes Treatment Supply Chain Analysis
8.1.1 Herpes Treatment Supply Chain Analysis
8.1.2 Covid-19 Impact on Herpes Treatment Supply Chain
8.2 Distribution Channels Analysis
8.2.1 Herpes Treatment Distribution Channels
8.2.2 Covid-19 Impact on Herpes Treatment Distribution Channels
8.2.3 Herpes Treatment Distributors
8.3 Herpes Treatment Customers
9 Key Findings
10 Appendix
10.1 About Us
10.2 Disclaimer
